Smith & Nephew - SNN STOCK NEWS

Smith+Nephew (NYSE:SNN) has launched RI.INSIGHTS, a pioneering platform aimed at enhancing robotics-assisted surgeries. This tool allows orthopedic surgeons to benchmark their surgical experiences against peers and utilize intra and post-operative data to improve patient outcomes. The platform, part of the Real Intelligence portfolio, aims to drive advancements in digital health and robotics surgery. Currently available on a limited basis, a full commercial release is planned for 2021. Smith+Nephew generated $5.1 billion in sales in 2019, emphasizing its commitment to innovation in orthopedic technology.

Smith+Nephew (NYSE:SNN) announced positive two-year follow-up results from the STITCH Study for its NOVOSTITCH Meniscal Repair Systems. This first-of-its-kind trial demonstrated an impressive clinical success rate of 82.6%, with significant improvements in all Patient Reported Outcome Measures (PROMs) at p<0.001. Complete meniscal healing was observed in 100% of patients evaluated at six months. The study emphasizes a shift towards meniscal repair, which could prevent long-term complications like osteoarthritis associated with meniscectomy. The NOVOSTITCH system offers innovative solutions for complex meniscal tears.

Smith+Nephew (NYSE:SNN) has enhanced its ARIA digital care management platform with new tools: ARIA SiteSelect and ARIA Optimized Recovery Pathways. These innovations aim to assist clinicians in accurately determining suitable outpatient surgery candidates and standardizing total joint care pathways for improved post-operative outcomes. Utilizing patient history and lifestyle data, ARIA SiteSelect helps identify optimal surgical sites, while the 90-day recovery pathways are designed to reduce complications and enhance patient mobility post-surgery.

Smith+Nephew (NYSE: SNN) has announced the upcoming launch of ARIA Home PT, a remote physical therapy module for its ARIA digital care management platform, set for early 2021. This module includes a virtual coaching system utilizing 3D motion capture technology, aiming to enhance patient recovery and expand access to post-acute care. Telehealth functionalities will follow soon after. The initiative is part of Smith+Nephew's investment in its Positive Connections program, addressing the growing demand for digital health solutions.

Smith+Nephew (NYSE:SNN) has been awarded Most Innovative at the 2020 Gartner Communications Awards for its T.I.M.E. clinical decision support tool (CDST), which addresses the lack of consistent wound assessment practices among specialists. Developed through collaboration with international experts, the tool aims to improve clinical outcomes by standardizing care delivery. The campaign has seen significant customer engagement, generating multiple publications and a consensus document by the World Union of Wound Healing Societies. This recognition highlights Smith+Nephew’s commitment to enhancing patient care and stakeholder engagement.

Smith+Nephew (NYSE:SNN) has partnered with Avail Medsystems to implement remote collaboration services in operating rooms. This innovative approach allows healthcare professionals to support procedures without being physically present, enhancing efficiency in hospitals and ASCs where space is limited. The Avail System features HD cameras and a split-screen display for real-time interaction. Smith+Nephew aims to improve surgical education and access to expertise while reducing capital investments. This initiative aligns with their mission to enhance medical technology and demonstrates adaptability in a changing healthcare environment.

Smith+Nephew has launched the HEALICOIL KNOTLESS Suture Anchor, enhancing its Advanced Healing Solutions portfolio for rotator cuff repairs. This innovative product utilizes a unique open architecture design with REGENESORB Material, promoting faster bone healing and less foreign material in the body. Clinical insights suggest superior healing at the tendon-bone interface. The company aims to redefine healing potential, reinforcing its commitment to patient recovery. Annual sales reached $5.1 billion in 2019, with a strong presence in over 100 countries.

Smith+Nephew (NYSE:SNN) has launched its NOVOSTITCH PRO Meniscal Repair System in Europe following CE mark certification. This innovative system aims to address the needs of around 600,000 European patients annually suffering from meniscal tears, a common orthopedic injury. Traditionally, many patients undergo partial or complete meniscectomy, increasing their risk of osteoarthritis. The NOVOSTITCH PRO system allows surgeons to perform repairs more effectively in tight joint compartments. Initial clinical experiences have been positive, with surgeons highlighting its versatility and potential to improve patient outcomes.

Smith+Nephew (NYSE: SNN) launched ARIA, a digital platform aimed at enhancing patient care by improving communication between patients and providers during surgical episodes. Powered by the Real Intelligence ecosystem, ARIA helps reduce recovery times, minimize costs, and gather Patient Reported Outcome Measures (PROMs). The platform integrates secure communication and customizable pathways, leading to actionable data for surgery centers and enhancing efficiencies. Prior technology acquisitions are foundational to ARIA's capabilities, including a documented 45% reduction in readmissions in previous implementations.